State of Alaska Department of Revenue Trims Stock Position in DaVita Inc. $DVA

State of Alaska Department of Revenue decreased its holdings in shares of DaVita Inc. (NYSE:DVA) by 9.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,659 shares of the company’s stock after selling 495 shares during the period. State of Alaska Department of Revenue’s holdings in DaVita were worth $663,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Doma Perpetual Capital Management LLC grew its holdings in shares of DaVita by 172.3% in the 1st quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock worth $44,110,000 after acquiring an additional 182,476 shares during the period. Northern Trust Corp grew its holdings in DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after buying an additional 149,858 shares during the last quarter. Nuveen LLC acquired a new stake in DaVita during the 1st quarter valued at $20,218,000. Rovin Capital UT ADV acquired a new stake in DaVita during the 1st quarter valued at $18,442,000. Finally, Amundi grew its holdings in DaVita by 16.0% during the 1st quarter. Amundi now owns 517,690 shares of the company’s stock valued at $79,584,000 after buying an additional 71,304 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DVA shares. Truist Financial set a $148.00 price target on DaVita in a research note on Friday, August 8th. Bank of America reduced their price target on DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a research note on Wednesday, September 10th. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research note on Saturday, September 27th. Barclays reduced their price target on DaVita from $169.00 to $160.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 7th. Finally, Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $158.00.

Insider Transactions at DaVita

In other news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the transaction, the insider directly owned 26,038 shares of the company’s stock, valued at $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.50% of the company’s stock.

DaVita Trading Up 2.3%

NYSE:DVA opened at $131.09 on Wednesday. The business’s fifty day moving average price is $134.17 and its 200 day moving average price is $139.76. DaVita Inc. has a 1-year low of $126.07 and a 1-year high of $179.60. The firm has a market capitalization of $9.37 billion, a price-to-earnings ratio of 12.89, a PEG ratio of 0.92 and a beta of 1.13.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The company had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.36 billion. During the same period in the prior year, the company earned $2.00 earnings per share. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Equities analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.